Abstract / Summary
This cross-sectional study examines how use of glucagon-like peptide-1 (GLP-1) receptor agonists varies among US adults with diabetes with or without a history of cancer.
Topics
Diabetes Treatment and ManagementOpen access
Primary Source
JAMA Network Open